4th annual

European Antibody Congress 2008

1 – 3 December 2008, Crowne Plaza Hotel, Geneva, Switzerland

Europe's premier antibodies event

Register before 19 September and save up to £249!

Day one: understanding structure function relationships

Dr Scott Glaser
Director, Molecular Engineering
Biogen Idec

Dr Tristan Vaughan
Senior Director, Lead Generation
MedImmune

Dr Juan Carlos Almagro
Head, Antibody Design Group
Centocor

Day two: antibodies: challenges and opportunities

Dr Stefan Bassarab
Director, Pharmaceutical Development
Boehringer Ingelheim

Professor Jan van de Winkel
Chief Scientific Officer
Genmab

Jonathan Klein-Evans
Vice President, Intellectual Property
MedImmune

Day three: antibody innovation and antibody alternatives

Dr Mark Sliwkowski
Director, Translational Oncology
Genentech

Dr Eric Furfine
Senior Vice President, Research and Preclinical Development
Adnexus

Dr Andreas Plückthun
Professor of Biochemistry
University of Zurich

Attack.

Discover. Develop. Get to market.

- Europe's largest and most influential antibody and antibody alternative event
- Dedicated to the future development of the antibody market in Europe and beyond
- The most impressive mix of expert speakers from global pharmaceutical companies, cutting edge biotechs, research organisations and academia
- Build new relationships and future partnerships with more hours of dedicated networking than any other antibody event

Including presentations from the following companies:

Genentech, Roche, Abbott, Novartis, Merck, Centocor, MedImmune, Biogen Idec, Genzyme, Adnexus, Domantis, Boehringer Ingelheim, Kyowa Hakko Kogyo, Pierre Fabre, ImmunoGen, Medarex, Genmab, Seattle Genetics, Micromet, Dyax… and many more.

Event sponsors and exhibitors

MedImmune
PALL Life Sciences
Filtration. Separation. Solution.
INNOVATIS
Piramal Healthcare
M-Scan
ProGenosis
bucher biotec
sloning BioTechnology
C/M/C biologics
Molecular Devices
now part of MDS Analytical Technologies

Organised by

terrapinn
use your brain

www.terrapinn.com/2008/antibody

Attack.

The complete antibody event for science, business

Europe's largest forum for the advancement of antibody discovery and development

Monoclonal antibodies are currently delivering the fastest growth in the pharmaceutical industry, achieving a compound annual growth rate of around 14%, and driving the value of the biologics market towards $106 billion by 2010. In the last 10 years monoclonal antibodies have had a massive impact on the pharmaceutical industry. At the same time, our understanding of therapeutic target identification, antibody structure-function relationships and the remarkable potential of monoclonal antibodies for treating patients continues to grow. Nevertheless, this is a pivotal period for the future of antibody and antibody alternative development, and there are many questions that need to be answered to maximise the extraordinary impact of monoclonal antibodies and antibody alternatives.

About the congress

The 4th annual *European Antibody Congress* is Europe's largest and most influential antibodies and antibody alternatives event, bringing together business leaders and the foremost scientists from across the industry. This lively and energetic meeting combines expert speakers, cutting-edge case studies and dedicated networking in an environment where debate is encouraged and discussion thrives. This year's congress focuses on the opportunities, challenges and critical scientific developments identified during thorough research with over 250 key individuals working with monoclonal antibodies. As such this is the leading platform in Europe to help drive the future of antibody development, and allows your business to capture the key opportunities in the antibody sector.

Att

Cutting edge discussion from…

Global experts on understanding structure-function relationships

This year, we are proud to present some of the world's foremost authorities and leading thinkers on understanding structure-activity relationships of monoclonal antibodies. Chairing the session is **Alain Beck** of **Pierre Fabre,** a widely recognised expert in monoclonal antibody research and development. We are also delighted to welcome **Andrew Goodearl** of **Abbott.** As Director of Abbott's Bioresearch Center he is ideally suited to contribute to this meeting and will give an overview of isotype selection in monoclonal antibody engineering. Other highlights include **Juan Carlos Almagro** who heads antibody design at **Centocor, Tristan Vaughan,** Senior Director of Lead Generation at **MedImmune, Laurent Audoly,** Senior Director of the Department of Biologic Research at **Merck & Co,** and **Scott Glaser,** Director of Molecular Engineering at **Biogen Idec.**

Antibody business leaders, thinkers and strategists

This is a critical time for monoclonal antibodies, with major challenges to overcome and opportunities to be exploited. We are delighted to welcome **Jonathan Klein-Evans** who oversees all intellectual property issues for **MedImmune,** to guide us on the important existing and forthcoming legal challenges affecting antibody development. Also on the agenda is **Janice Reichert** of the **Tufts Center for the Study of Drug Development** who is universally recognised as the world's leading authority on historic and emerging trends and developments in the monoclonal antibodies sector. A leading thinker in the antibodies sector, **Jan van de Winkel,** Chief Scientific Officer of **Genmab,** will also outline successful approaches to antibody lead identification and optimisation. Among others, we will also hear from **Patrick Liu** of **Genentech** assessing immunogenicity strategies for antibody therapeutics and **Stefan Bassarab,** Director of Pharmaceutical Development for **Boehringer Ingelheim** who will outline challenges and state-of-the-art developments in the clinical delivery of monoclonal antibodies.

The World's leading scientists and innovators

We are pleased to welcome the internationally-renowned **Mark Sliwkowski,** Director of Translational Oncology at **Genentech** who will outline work and clinical updates on an advanced antibody-drug conjugate based on Herceptin. **Andreas Plückthun** from the **University of Zurich** will also be present to outline the latest work in engineering repeat proteins for tumour-targeting. There will be updates from **Chengbin Wu** of **Abbott** and **Christian Itin,** Chief Executive Officer and President of **Micromet** who will discuss their work with bi-specific antibodies. We end the congress with an in-depth focus on the very latest developments in antibody alternatives with **Eric Furfine** of **Adnexus, Dimiter Dimitriov** of **NIH** and **Ruud de Wildt** of **Domantis** among others, who round off a packed agenda by covering the very latest preclinical and clinical developments in antibody alternatives.

> "Terrapinn's annual *European Antibody Congress* is definitively a major event in the biopharmaceutical world. This meeting brings together representatives of big pharma, biotechs, start-up companies, CRO/CMOs, consultants, regulatory authorities and academics. All is done by the organisers to offer a great program with hot presentations, case studies and interactive panel sessions. Scientific and business networking opportunities are maximised in a casual atmosphere."
>
> **Dr Alain Beck,** Head of Physico-Chemistry Department, Center of Immunology, **Pierre Fabre**

What's in

- Hear the latest from the giants of antibody development: the likes of **Abbott, Genentech, MedImmune, Roche, Biogen Idec, Merck, Centocor, Genzyme, Novartis, Boehringer Ingelheim, Domantis** and **Adnexus** will be present
- **Day one –** add value to your antibody research and development programmes with **structure-activity insights** from acknowledged world-leading experts in the area

strategy and networking

ack.

> Europe is a hotbed of science and ideas with respect to biologics, and many of the most significant innovations in biologics and the monoclonal antibody field have come from European research. It is exciting to be able to attend the *European Antibody Congress* which is centered around so many new ideas in the cradle of biologics discovery.
>
> **Dr William Strohl,** Executive Director, Department of Biologics Research, **Merck & Co.**

it for you?

- **Day two –** get the latest perspectives on the hot issues, including **immunogenicity, biosimilars, intellectual property issues, regulatory developments, antibody resistance, optimising production** and **the generation of antibodies against new targets**
- **Day three –** gain valuable insights into the very latest **preclinical and clinical developments** in **antibody-drug conjugates, bi-specific antibodies** and **antibody alternatives**

More hours of dedicated networking than any other antibody event

contact Introducing you to your customers, your peers and your suppliers. 'Contact' is Terrapinn's unique online introductory service. It's a simple system designed with event attendees in mind, giving you the list of attendees and the option to email them. Don't leave meeting the best event attendees to chance. Contact them before and after the event. You can also download speaker presentations and white papers after the event.

SPEED NETWORKING This is the revolutionary, exciting and non-pressured way to meet fellow congress attendees and industry peers in a 60 minute session. It is a part of the formal congress agenda. These brief meetings are the starting point for conversation and networking throughout the congress, and are where long lasting and profitable business relationships begin. Make sure you bring lots of business cards!

PANEL SESSION The congress programme includes several panel sessions. These are chat show style sessions creating an interactive environment rather than a lecture. The panellists are chosen for their views and lively debate is encouraged. This is your chance to interact and put your questions to the panel to ensure that the experts answer the questions that are relevant to your business.

This networking drinks reception is a great opportunity to meet other attendees after the congress day ends. Held at the end of the first main congress day, this is your perfect opportunity to network with your peers in a casual setting. This is a relaxed, informal and entertaining event.

The Crowne Plaza Geneva is a luxurious hotel perfectly located next to the international airport (0.5 KM), close to the city centre and Lake Geneva. The largest hotel in Switzerland, the Crowne Plaza offers everything you would come to expect from a superior business-orientated venue: WIFI and ADSL internet connections, a large business centre, advanced fitness centre, indoor heated swimming pool and three different restaurants. Many of the key sightseeing attractions such as the United Nation Place, the Red Cross Museum as well as Geneva's fantastic shopping district are reachable within only 10min. Please visit **www.cphotel.ch** for more information.

The Terrapinn difference

- Real case studies presented by CEOs
- Powerpoint actively discouraged. Interaction encouraged
- Q&A sessions are a formal part of the proceedings
- Panel sessions create a talk show rather than a lecture
- Buffet lunches that encourage networking
- Speed networking increasing the number of people you meet
- Contact: facilitating networking before, during and after the event
- Drinks receptions to network and relax
- A year long, extensive marketing campaign
- Real value for sponsors and speakers
- Music: tune into event theme

Book before 19 September and save up to £249!

Join our existing attendees at this exciting event. Fax back the registration form to +44 (0)20 7242 2320 or register online at www.terrapinn.com/2008/antibody

Attack.

Therapeutic antibodies: advances in understanding the structure-function relationship

Day One Monday 1st December 2008

08.00 **Registration and coffee**

09.00 **Chairman's opening remarks**
Dr Alain Beck, Head of Physico-Chemistry Department, **Centre d'Immunologie Pierre Fabre**

THE RIGHT ANTIBODY ISOTYPE FOR THE RIGHT FUNCTION

09.05 Keynote presentation: **isotype selection in monoclonal antibody engineering: choosing the right format for success**
- A critical overview of monoclonal antibody engineering
- Considering IgG isotype properties
- Isotype selection principles and case studies

Dr Andrew Goodearl, Director, **Abbott Bioresearch Center**

09.30 **Natural IgG4 half antibodies, *in vivo* bispecific antibody rearrangement and implications for IgG4 activity**
- IgG4 structural rearrangement studies and findings
- Implications for IgG4 anti-inflammatory activity

Dr Rob Aalberse, Head, Department of Immunochemistry, **Sanquin Research**

ANTIBODY/ANTIGEN COMPLEXES: STOECHIOMETRY AND EPITOPE/PARATOPE MAPPING

09.55 **Antibody epitope mapping: structural basis for better functional activity understanding**
- Structural and functional mapping methods: case studies
- Impact for second generation monoclonal antibody research and development, and effects on Intellectual Property

Dr Alain Beck, Head of Physico-Chemistry Department, **Centre d'Immunologie Pierre Fabre**

10.20 **Speed networking**

11.20 **Morning coffee**

11.40 **Case studies on structure-function analysis**
- Outlining approaches to antibody epitope characterisation
- Importance of Fc-mediated effector function for antibodies
- Case studies of structure-function analysis

Dr Paul Parren, Senior Vice President, Research and Development, **Genmab**

12.05 **Enhancing IP protection via epitope mapping**
- Antibody patent level of protection and implications
- Distinguishing antibodies: obtaining meaningful patent protection

Dr Kathleen Madden Williams, Intellectual Property Attorney, **Edwards, Angell, Palmer & Dodge**

12.30 **The Bifunctional Hybrid Protein (BHP): a new enabling technology for non-linear epitope mapping**
- Identification of epitope region and key amino acid determination using BHP technology as a BioTool
- Enabling a unique and original epitope display

Dr Fabrizio Gianotta, Chief Executive Officer, **Progenosis**

12.55 **Lunch**

ANTIBODY VH ENGINEERING TO REDUCE IMMUNOGENICITY AND ENHANCE PHARMACOLOGY

14.00 **V region engineering to reduce immunogenicity and enhance functional and biophysical properties**
- Humanisation via specificity-determining residues usage resurfacing
- Manipulation to enhance affinity and cross-reactivity
- Assessing and removing chemical stability liabilities

Dr Juan Carlos Almagro, Head of Antibody Design, **Centocor**

14.25 **Stability-engineered IgG-like tetravalent antibody for inducing receptor-mediated death in leukemia cells**
- Design and production of IgG-like tetravalent antibodies
- Receptor cross-linking enhances tumour cell apoptosis

Dr Scott Glaser, Director, Molecular Engineering, **Biogen Idec**

14.50 **The role of residue isomerisation in complimentary determining regions**
- Important CDR variables governing antibody/antigen reactivity
- Determining the effect of residue isomerisation on binding
- Clinical implications for future antibody development

Dr Tristan Vaughan, Senior Director, Lead Generation, **MedImmune**

ANTIBODY FC AND FAB GLYCOSYLATION

15.15 **Engineering differentiating pharmacology in monoclonal antibodies using protein- and glyco-engineering**
- Leveraging glyco-engineering in monoclonal antibodies
- Integration of glyco-engineering into novel Fc variants to maximise pharmacological efficacy

Dr Laurent Audoly, Senior Director, Department of Biologic Research, **Merck & Co**

15.40 **Afternoon tea**

16.10 **Antibodies with maximum effector functions, based on natural IgG isotypes and oligosaccharide heterogeneity**
- Shortcomings of current generation antibody therapeutics
- The importance of improving low *in vivo* efficacy
- A new design of next-generation therapeutic antibodies based on the natural IgG isotype

Dr Mitsuo Satoh, Director, Antibody Research Laboratories, **Kyowa Hakko Kogyo**

16.35 **Glycosylation for enhancing antibody effector functions**
- Overview of the functional implication of glycosylation states
- Methods for metabolically modulating glycosylation
- Time-efficient production of antibodies with increased antibody-dependent cellular cytotoxicity

Dr Qun Zhou, Senior Scientist, **Genzyme**

17.00 **GA101, a novel glyco-engineered type II CD20 antibody with outstanding anti-tumour efficacy and superior B cell depletion**
- The mode of action of type I and type II CD20 antibodies
- Consequences of glyco-engineering of the type II GA101 and differentiating properties of GA101
- An outlook on GA101 and glyco-engineering

Dr Christian Klein, Head of Discovery Oncology, **Roche**

17.25 **The pro- and anti-inflammatory activities of IgG**
- The role of complement and Fc-receptors for antibody activity *in vivo*
- Impact of fucose, galactose and sialic acid
- Implications for the optimisation of therapeutic antibodies and enhancement of the anti-inflammatory activity
- Mechanistic insights in the anti-inflammatory pathway

Professor Falk Nimmerjahn, Associate Professor of Immunology, **University of Erlangen-Nuremberg**

17.50 Panel session: **translation of antibody structure-function knowledge in clinical drug candidates**
- Choosing the best antibody isotype, epitope mapping, and modulation of effector functions

Moderator:
Dr Luc-Alain Savoy, Director, **M-Scan SA**
Panellists:
Dr Alain Beck, Head of Physico-Chemistry Department, **Centre d'Immunologie Pierre Fabre**
Dr Tristan Vaughan, Senior Director, Lead Generation, **MedImmune**
Dr Andrew Goodearl, Director, **Abbott Bioresearch Center**

18.20 **Close of day one followed by networking drinks**

Antibodies: challenges and opportunities

Day Two Tuesday 2nd December 2008

08.00 **Registration and coffee**

09.00 **Chairman's opening remarks**
Dr Clive Wood, Chief Scientific Officer, **Dyax**

09.05 **Keynote presentation: an evidence-based perspective on emerging trends and developments**
- Monoclonal antibodies approved for market globally
- Marketing approval success rates and some key indicators
- Making predictions for the future

Dr Janice Reichert, Senior Research Fellow, **Tufts Center for the Study of Drug Development** and Editor-in-Chief, **mAbs**

09.30 **A case study in successful pipeline discovery and development**
- Optimising development capability: selecting antibody candidates for development and choosing the best
- Accelerating development into the clinic
- Wider perspectives on the possibilities for antibodies

Professor Jan van de Winkel, Chief Scientific Officer, **Genmab**

09.55 **A European regulator's perspective on monoclonal antibody development and regulation**
- An overview of current European regulation
- Planning for the future of antibodies and antibody alternatives
- Current activities of regulators and future challenges

Dr Kowid Ho, Head of Biological Products, Biological Evaluation Division, **AFSSAPS**

10.20 **Morning coffee**

ANTIBODY FORMULATION AND DELIVERY

10.50 **Considerations for formulation, and enhancing the 'drug-like' qualities of monoclonal antibodies**
- High throughput formulation of monoclonal antibodies
- Drug stability, aggregation, and characterisation
- Formulation case studies of monoclonal antibodies

Professor Tudor Arvinte, Professor of Biopharmaceuticals, **University of Geneva,** and Chief Executive Officer, **Therapeomic**

11.15 **Delivery of monoclonal antibodies: state of the art delivery and associated challenges**
- The need of highly concentrated antibody formulations
- Stability-points to consider, and how to improve
- Excipients, technologies, devices and administration

Dr Steffan Bassarab, Director, Pharmaceutical Development, **Boehringer Ingelheim**

CLINICAL CONSIDERATIONS FOR ANTIBODY DEVELOPMENT

11.40 **Investigating and circumventing resistance to therapeutic monoclonal antibodies**
- Preclinical models for investigation
- The impact of glycoengineered antibodies
- Resistance mechanisms, prediction and clinical relevance

Dr Charles Dumontet, Deputy Vice President, Scientific Hematology Laboratory, **University Hospital, Lyon**

12.05 **Immunogenicity assessment of antibody therapeutics**
- Strategies and tools for characterising immunogenicity
- Perspectives on risk assessment for immunogenicity
- Regulatory guidelines on immunogenicity assessment

Dr Patrick Liu, Associate Director, Development Sciences, **Genentech**

12.30 **Lunch**

PATENTING, INTELLECTUAL PROPERTY AND BIOSIMILARS

13.30 **Patenting and Intellectual Property**
- Assessing the true impact of patent expiry
- Structuring your R&D for maximum IP capture
- European and US patent law: what you need to do

Jonathan Klein-Evans, Vice President, Intellectual Property, **MedImmune**

13.55 **Biosimilar antibodies – reality or a distant dream?**
- Current EU biosimilar guidelines, successes and failures
- Advantages and disadvantages of biosimilar antibodies
- Applying for biosimilar antibody market authorisation

Dr Keith Watson, Pharmaceutical Assessor, Biologicals and Biotechnology Unit, **Medicines and Healthcare Products Regulatory Agency (MHRA)**

ENHANCED PRODUCTION SYSTEMS FOR MONOCLONAL ANTIBODIES

14.20 **Optimising the production of monoclonal antibodies in mammalian cells**
- Assessing key achievements and technical challenges
- Developing cell culture processes to optimise yield
- Future optimisation: growing trends and industry activity

Dr Hitto Kaufmann, Associate Director of Cell Biology, **Boehringer Ingelheim**

14.45 **Real-time control of antibody development and the production process to support a Quality by Design approach**
- Current status of PAT and QbD approaches
- Requirements of real-time analysis in bioprocessing
- PAT Bioplatform for antibody development and production
- Support of global task sharing and process comparison

Andreas Schneider, Director, Global Sales, **Innovatis**

15.10 **Afternoon tea**

GENERATION OF ANTIBODIES AGAINST NEW TARGETS

15.40 **Discovery and development of cancer antibodies using functional screens**
- Generating and selecting antibodies based on activity
- Focusing on antibody epitope efficacy and using cell signal or cell death as a measurable
- Outline of antibody candidates developed this way

Dr David Young, Chairman, President and Chief Executive Officer, **ARIUS**

16.05 **Discovery of anti-cancer monoclonal antibodies targeting JAM-A by functional approaches**
- Functional approaches and proteomics
- Innovative targets for oncology
- Anti-proliferative antibodies

Dr Nathalie Corvaïa, Head of Research, **Centre d'Immunologies Pierre Fabre**

STATE OF THE ART METHODS FOR ANTIBODY METABOLICS AND PHARMOKINETICS

16:30 **Quantification of recombinant monoclonal antibodies in biological fluids for faster biotherapeutic development**
- Current methods for antibody quantification and limitations
- Designing a procedure for antibody quantification

Dr Francis Bitsch, Senior Scientist, **Novartis**

16.55 **Close of day two followed by networking drinks**

Attack.

Innovation in antibody and antibody alternatives development

Day Three Wednesday 3rd December 2008

09.00 **Chairman's opening remarks**
Dr Bob Lutz, Senior Director, Preclinical Development, **ImmunoGen**

ADVANCES IN CONJUGATE ANTIBODIES – UPDATES AND LEADING TECHNOLOGIES

09.05 **Development of advanced antibody-based therapeutics in oncology**
- Introduction to antibody-drug conjugate development
- Conjugate design and impact on activation / performance
- Case study: antibody-maytansinoid conjugate overview
- Clinical update for antibody-maytansinoid conjugate drugs

Dr Bob Lutz, Senior Director, Preclinical Development, **ImmunoGen**

09.35 **Keynote presentation: Trastuzumab DM1 (T-DM1): an advanced antibody-drug conjugate based on Herceptin**
- Dual strategy of T-DM1: anti-HER2 activity and targeted intracellular delivery of cytotoxic DM1
- Phase I clinical data
- Overview of ongoing Phase II clinical trials evaluating for HER2-positive metastatic breast cancer

Dr Mark Sliwkowski, Director, Translational Oncology, **Genentech**

10.05 **Auristatin based antibody-drug conjugates: preclinical and clinical update**
- Impact of drug- and linker types on therapeutic activity
- The role of target biology in the selection of optimal drug-linker combinations
- Clinical update on antibody-auristatin conjugates

Dr Hans-Peter Gerber, Director, Translational Biology, **Seattle Genetics**

10.35 **Human antibody-MGBA conjugates for cancer therapy**
- Overview of antibody-MGBA conjugates, including mechanism of action and their advantages and disadvantages
- Human antibody selection and conjugate optimisation
- Update on conjugates in development

Dr David King, Senior Director, Biochemistry and Molecular Biology, **Medarex**

11.05 **Morning coffee**

FOCUS ON BI-SPECIFIC ANTIBODIES

11.35 **Development of a dual-specific antibody technology: DVD-Ig**
- Development of advanced biologics to enhance efficacy
- Platform technology with strategic benefits for R&D
- Production / manufacturing issues for bispecific antibodies
- A novel approach for life-cycle management of existing antibody drugs

Dr Chengbin Wu, Senior Scientist, **Abbott**

12.05 **An update on bispecific T-Cell Engager (BITE®) technology**
- A brief overview of BITE® platform technology
- BITE® structure and mechanism
- Drug pipeline and clinical update

Dr Christian Itin, President, Chief Executive Officer and Director, **Micromet**

BEYOND ANTIBODIES: NEW BINDING SCAFFOLDS AND EMERGING TECHNOLOGIES

12.35 **Adnectins™: realising the promise of a novel class of targeted biologics**
- Origin and development of Adnectins™
- Advantages over traditional protein therapeutics – speed, manufacturing and multi-functionality
- Emerging clinical data from CT-322, and Adnectin inhibitor of VEGFR-2

Dr Eric Furfine, Senior Vice President, Research and Preclinical Development, **Adnexus, a Bristol-Myers Squibb Company**

13.05 **Lunch**

14.05 **Engineering repeat proteins for tumour-targeting**
- Overview of repeat proteins
- Preparation, characterisation and functionality
- Repeat proteins as tumour-targeting reagents

Dr Andreas Plückthun, Professor of Biochemistry, **University of Zurich**

14.35 **Protease inhibitors from phage display**
- Proteases: a critical role in disease pathways but an unsuccessful small molecule drug target
- Designing phage display library selections to yield highly selective and potent protease target inhibitors
- Serine and metallo-protease inhibitor proteins: from phage display to the clinic

Dr Clive Wood, Chief Scientific Officer, **Dyax Corp**

15.05 **Pulmonary delivery of domain antibodies as drugs**
- Preclinical and clinical data of domain antibody-based drugs
- Proof-of-concept for pulmonary delivered domain antibodies
- Advantages over conventional antibody-based therapies
- Clinical utility of domain antibodies for treatment of pulmonary disease

Dr Ruud de Wildt, Manager, Biopharm CEDD, **Domantis**

15.35 **Afternoon tea**

16.00 **Nanoantibodies: novel scaffolds based on human antibody constant domains**
- Nanoantibodies: rationale, structure and work-to-date
- Assessing the advantages of nanoantibodies over similar binding scaffolds
- Testing of nanoantibodies for functional activity in animal models

Dr Dimiter S Dimitrov, Head, Protein Interaction Group, Senior Investigator, **NIH**

16.30 **Small antibody-mimicking structures for therapeutic applications**
- The development of small (< 2000 Da) antibody-mimicking structures that are built of an organic molecule core and peptide loops that are anchored to this core
- The isolation of antibody-mimicking structures with high affinity and specificity for biological targets
- Critical qualities: small size, unique structure and high stability
- Potential advantages: efficient tissue penetration, low immunogenicity and low manufacturing costs

Dr Christian Heinis, MRC Laboratory of Molecular Biology, **University of Cambridge**

17.00 **Panel discussion: assessing the market impact of domain/ fragment approaches on classical antibody development**
- Anticipating the competition between antibody domain/ fragment approaches and IgG-based drugs
- Overcoming regulatory hurdles associated with new approaches, strategic (and financial) commitment and assessing patient benefit
- Strategic opportunities for building an appropriate antibodies pipeline

Moderator:
Dr Bob Lutz, Senior Director, Preclinical Development, **ImmunoGen**
Panellists:
Dr Clive Wood, Chief Scientific Officer, **Dyax Corporation**
Dr Mark Sliwkowski, Director, Translational Oncology, **Genentech**
Dr Eric Furfine, Senior Vice President, Research and Preclinical Development, **Adnexus, a Bristol-Myers Squibb Company**

17.30 **Close of Congress**

Target Europe's largest and most influential antibody event in 2008

Monoclonal antibodies are currently the fastest growing sector of the biopharmaceutical industry. They possess colossal potential to revolutionise the treatment of a variety of unmet diseases and disorders. Companies already supplying this market are clamouring to be the supplier of choice as pharma and biotech take developments to the next level. Those new to this industry, however, need to find their commercial angle in gaining a strategic foothold.

Create and nurture new business relationships

Building on the success of the previous three years, the *European Antibody Congress* will continue to serve as Europe's most influential meeting place for the antibody community in 2008 and beyond. The congress continues to support the antibody industry by connecting biotechs, pharmaceutical companies and antibody manufacturers with the suppliers they need to get the job done.

The *European Antibody Congress* offers a succinct promotional and commercial development solution to companies that wish to position themselves at the forefront of the antibody sector. This is a major opportunity to enhance branding, reputation and sales by engaging face-to-face with your target audience.

If your company falls into one of the categories below then the *European Antibody Congress* offers you a unique platform to stand out from the crowd:

Who should sponsor or exhibit?

- Antibody suppliers
- Biotechs
- Consultants
- Contract antibody providers
- Contact manufacturing organisations
- Contract research organisations
- Engineering and construction
- Law firms
- Outsourced bioanalytics
- Processing equipment/ software providers
- Protein licensors
- Regional development agencies
- Technology providers

A complete marketing and sales solution

We provide solutions via direct marketing, telemarketing, advertising, internet and email campaigns, as well as through our press contacts and tailored promotional initiatives. This is your chance to be seen as a market leader and to present your message to executives driving the global antibody market.

Come and network with industry leaders, generate leads, promote your services, increase your company's profile or just show the world that you're still at the front of the pack.

Who has attended this event in the past?

Take a look at who has previously attended the *European Antibody Congress.* You can be sure that you will meet decision-makers from your target market, giving you the highest possible return on investment.

YOUR partners, customers, prospects and competitors will be there. Will you?

Why wait? The earlier we confirm your participation, the sooner we can include you in our marketing campaign and expose your brand to our extensive database of antibody contacts. Contact Sylvester Gabriel on +44 (0) 207 827 5994 or email sylvester.gabriel@terrapinn.com to tailor your package.

Our sponsors and exhibitors

Our media partners

Delegate by job title



Organisation by industry type



Response form **Fax Back to +44 (0)20 7242 1508**

☐ **Yes!** I am interested in sponsorship opportunities. Please contact me immediately.

☐ **Yes!** I am interested in exhibiting. Please contact me immediately.

Name:..... Job title:.....

Company:.....

Address:.....

Tel:..... Fax:..... Email:.....

Code: 14/1395

Registration form

European Antibody Congress 2008

1 – 3 December 2008, Crowne Plaza Hotel, Geneva, Switzerland

5 easy ways to register

Phone: +44 (0)20 7242 2324
Fax: +44 (0)20 7242 2320
Online: www.terrapinn.com/2008/antibody
Email: sarah.pegden@terrapinn.com
Post: Terrapinn Ltd, Wren House,
43 Hatton Garden London, EC1N 8EL, UK

Yes, please register me for:

Package	Dates	Received before 19 Sept 2008	Received after 19 Sept and before 17 Oct 2008	Received after 17 Oct 2008
☐ 3 day conference	1-3 December 2008	£2,245.50 **SAVE £249.50!**	£2,370.25 **SAVE £124.75!**	£2495

☐ 50% discount for government, academia and non profit organisations

* The registration fee includes lunch, refreshments and full conference documentation. The fee does not include hotel accommodation. Payment terms are 14 days.

Corporate groups. Yes, I want to send the team and save even more.

Delegates	Package	Normal price	Group price	Total savings
☐ 3	Gold pass	£7,485	£6,736.50	**SAVE £748.50!**
☐ 6	Gold pass	£14,970	£11,976	**SAVE £2,994!**
☐ 8	Gold pass	£19,960	£14,970	**SAVE £4,990!**

**Corporate booking prices cannot be used in conjunction with any other promotional prices

Attendee details

	Mr/Mrs/Ms	Full name	Job title	Telephone	Email
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

For groups of more than 10 please attach a separate sheet with details of all attendees. Alternatively call +44 (0)20 7242 2324.

Company details

Signatory must be authorised to sign on behalf of contracting organisation

Name:.....

Job title:.....

Authorising signature:.....

Email:.....

Organisation name:.....

Industry:.....

Address:.....

Postcode:.....Country:.....

Tel:.....Fax:.....

Method of payment

Payment terms are 14 days. The conference registration pack will be sent to you once payment has been received.

☐ Bank Transfer ☐ Crossed cheque payable to Terrapinn Ltd
☐ Diners Club ☐ Visa ☐ American Express ☐ Mastercard

Card number: .....

Card holder's signature: .....

Expiry date: ..... Security code:.....

Bank Transfers: Account name: Terrapinn Limited, Sort code: 30-94-31, Bank Account Number: 0602538, Bank Name & Address: Lloyds TSB, 6 Holborn Circus, London EC1N 2HP, Swift Address: LOYDGB2L, IBAN: GB06 LOYD 3094 3100 6025 38, BIC: LOYDGB21037. **Reference: please quote 14/1395 and the delegate's name**

For official use only

Received: ☐ Date:.....Code 14/1395/A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Venue and hotel accommodation

Venue: Crowne Plaza Hotel Geneva
34 Route Francois-Peyrot, Geneva, 1218, Switzerland
Tel: + 41 22 747 0202, Fax: + 41 22 747 0303, www.cphotel.ch

Hotel accommodation:
The conference fee does not include accommodation. Terrapinn has obtained specially discounted rates for all attendees. A hotel booking form will be sent to all registered attendees. Please book early to avoid disappointment.

Data Protection

Terrapinn (or its agents) may contact you by mail, phone or email about products and services offered by Terrapinn and its group companies, which Terrapinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Terrapinn may also disclose your contact details to such third parties to enable them to contact you directly. Certain entities to which Terrapinn discloses your contact details are located in territories overseas which have fewer legal safeguards to protect personal data. By returning this form to us, you agree to our processing of your personal information in this way. Please tick the appropriate box if you do not wish to receive such information from:
☐ the Terrapinn group; ☐ or reputable third parties.

Cancellation

1. Should you be unable to attend, a substitute delegate is welcome at no extra charge.
2. Should you wish to cancel completely a charge of 50% of the registration fee, plus £150 (+ VAT) administrative charge will be made for cancellations received in writing at least 30 days prior to the conference start date.
3. Alternatively, you may choose a credit note for the full value of the registration price (valid for 1 year), which may be put towards another Terrapinn event.
4. The company regrets that no cancellations will be accepted within 30 days of the conference start date. Prepayments will not be refunded and invoiced sums will be payable in full, except in cases where it has been possible to mitigate loss.
5. Course documentation will, however be made available to the delegate. Terrapinn reserves the right to alter the programme without notice.

Insert your voucher code

Code:.....